Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

BACKGROUND: Tislelizumab is an investigational, humanized, IgG4 monoclonal antibody with high affinity and binding specificity for programmed cell death-1 (PD-1) that was engineered to minimize binding to FcγR on macrophages in order to abrogate antibody-dependent phagocytosis, a mechanism of T-cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Lin, Guo, Jun, Zhang, Qingyuan, Pan, Hongming, Yuan, Ying, Bai, Yuxian, Liu, Tianshu, Zhou, Qing, Zhao, Jun, Shu, Yongqian, Huang, Xiaoming, Wang, Siyang, Wang, Jie, Zhou, Aiping, Ye, Dingwei, Sun, Ting, Gao, Yujuan, Yang, Silu, Wang, Zuobai, Li, Jian, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304812/
https://www.ncbi.nlm.nih.gov/pubmed/32561638
http://dx.doi.org/10.1136/jitc-2019-000437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304812/
https://www.ncbi.nlm.nih.gov/pubmed/32561638
http://dx.doi.org/10.1136/jitc-2019-000437

Ejemplares similares